StemCell Therapy

The market research report published by QYResearch is a brilliant, in-depth, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Nucleic Acid Amplification Testing market. It informs readers about key trends and opportunities in the global Nucleic Acid Amplification Testing market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. On the whole, it comes out as an intelligent resource that companies can use to gain a competitive advantage in the global Nucleic Acid Amplification Testing market.

Key companies operating in the global Nucleic Acid Amplification Testing market include , F. Hoffmann-La Roche, Becton, Dickinson and Company, Beckman Coulter, Abbott Laboratories, Illumina, Siemens Healthineers, bioMerieux, Novartis, Bio-Rad Laboratories Nucleic Acid Amplification Testing

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/1528651/global-nucleic-acid-amplification-testing-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Nucleic Acid Amplification Testing market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Nucleic Acid Amplification Testing Market Segment By Type:

, Target Amplification Systems, Probe Amplification Systems, Signal Amplification Nucleic Acid Amplification Testing

Global Nucleic Acid Amplification Testing Market Segment By Application:

, Infectious Diseases, Cancer, Personalized Medicine, Genetic and Mitochondrial Disorders

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Nucleic Acid Amplification Testing market.

Key companies operating in the global Nucleic Acid Amplification Testing market include , F. Hoffmann-La Roche, Becton, Dickinson and Company, Beckman Coulter, Abbott Laboratories, Illumina, Siemens Healthineers, bioMerieux, Novartis, Bio-Rad Laboratories Nucleic Acid Amplification Testing

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/1528651/global-nucleic-acid-amplification-testing-market

TOC

Table of Contents 1 Report Overview1.1 Study Scope1.2 Key Market Segments1.3 Players Covered: Ranking by Nucleic Acid Amplification Testing Revenue1.4 Market Analysis by Type1.4.1 Global Nucleic Acid Amplification Testing Market Size Growth Rate by Type: 2020 VS 20261.4.2 Target Amplification Systems1.4.3 Probe Amplification Systems1.4.4 Signal Amplification1.5 Market by Application1.5.1 Global Nucleic Acid Amplification Testing Market Share by Application: 2020 VS 20261.5.2 Infectious Diseases1.5.3 Cancer1.5.4 Personalized Medicine1.5.5 Genetic and Mitochondrial Disorders1.6 Study Objectives1.7 Years Considered 2 Global Growth Trends by Regions2.1 Nucleic Acid Amplification Testing Market Perspective (2015-2026)2.2 Nucleic Acid Amplification Testing Growth Trends by Regions2.2.1 Nucleic Acid Amplification Testing Market Size by Regions: 2015 VS 2020 VS 20262.2.2 Nucleic Acid Amplification Testing Historic Market Share by Regions (2015-2020)2.2.3 Nucleic Acid Amplification Testing Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Top Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Porters Five Forces Analysis2.3.5 Nucleic Acid Amplification Testing Market Growth Strategy2.3.6 Primary Interviews with Key Nucleic Acid Amplification Testing Players (Opinion Leaders) 3 Competition Landscape by Key Players3.1 Global Top Nucleic Acid Amplification Testing Players by Market Size3.1.1 Global Top Nucleic Acid Amplification Testing Players by Revenue (2015-2020)3.1.2 Global Nucleic Acid Amplification Testing Revenue Market Share by Players (2015-2020)3.1.3 Global Nucleic Acid Amplification Testing Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.2 Global Nucleic Acid Amplification Testing Market Concentration Ratio3.2.1 Global Nucleic Acid Amplification Testing Market Concentration Ratio (CR5 and HHI)3.2.2 Global Top 10 and Top 5 Companies by Nucleic Acid Amplification Testing Revenue in 20193.3 Nucleic Acid Amplification Testing Key Players Head office and Area Served3.4 Key Players Nucleic Acid Amplification Testing Product Solution and Service3.5 Date of Enter into Nucleic Acid Amplification Testing Market3.6 Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026)4.1 Global Nucleic Acid Amplification Testing Historic Market Size by Type (2015-2020)4.2 Global Nucleic Acid Amplification Testing Forecasted Market Size by Type (2021-2026) 5 Nucleic Acid Amplification Testing Breakdown Data by Application (2015-2026)5.1 Global Nucleic Acid Amplification Testing Market Size by Application (2015-2020)5.2 Global Nucleic Acid Amplification Testing Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America Nucleic Acid Amplification Testing Market Size (2015-2020)6.2 Nucleic Acid Amplification Testing Key Players in North America (2019-2020)6.3 North America Nucleic Acid Amplification Testing Market Size by Type (2015-2020)6.4 North America Nucleic Acid Amplification Testing Market Size by Application (2015-2020) 7 Europe7.1 Europe Nucleic Acid Amplification Testing Market Size (2015-2020)7.2 Nucleic Acid Amplification Testing Key Players in Europe (2019-2020)7.3 Europe Nucleic Acid Amplification Testing Market Size by Type (2015-2020)7.4 Europe Nucleic Acid Amplification Testing Market Size by Application (2015-2020) 8 China8.1 China Nucleic Acid Amplification Testing Market Size (2015-2020)8.2 Nucleic Acid Amplification Testing Key Players in China (2019-2020)8.3 China Nucleic Acid Amplification Testing Market Size by Type (2015-2020)8.4 China Nucleic Acid Amplification Testing Market Size by Application (2015-2020) 9 Japan9.1 Japan Nucleic Acid Amplification Testing Market Size (2015-2020)9.2 Nucleic Acid Amplification Testing Key Players in Japan (2019-2020)9.3 Japan Nucleic Acid Amplification Testing Market Size by Type (2015-2020)9.4 Japan Nucleic Acid Amplification Testing Market Size by Application (2015-2020) 10 Southeast Asia10.1 Southeast Asia Nucleic Acid Amplification Testing Market Size (2015-2020)10.2 Nucleic Acid Amplification Testing Key Players in Southeast Asia (2019-2020)10.3 Southeast Asia Nucleic Acid Amplification Testing Market Size by Type (2015-2020)10.4 Southeast Asia Nucleic Acid Amplification Testing Market Size by Application (2015-2020) 11 India11.1 India Nucleic Acid Amplification Testing Market Size (2015-2020)11.2 Nucleic Acid Amplification Testing Key Players in India (2019-2020)11.3 India Nucleic Acid Amplification Testing Market Size by Type (2015-2020)11.4 India Nucleic Acid Amplification Testing Market Size by Application (2015-2020) 12 Central & South America12.1 Central & South America Nucleic Acid Amplification Testing Market Size (2015-2020)12.2 Nucleic Acid Amplification Testing Key Players in Central & South America (2019-2020)12.3 Central & South America Nucleic Acid Amplification Testing Market Size by Type (2015-2020)12.4 Central & South America Nucleic Acid Amplification Testing Market Size by Application (2015-2020) 13 Key Players Profiles13.1 F. Hoffmann-La Roche13.1.1 F. Hoffmann-La Roche Company Details13.1.2 F. Hoffmann-La Roche Business Overview and Its Total Revenue13.1.3 F. Hoffmann-La Roche Nucleic Acid Amplification Testing Introduction13.1.4 F. Hoffmann-La Roche Revenue in Nucleic Acid Amplification Testing Business (2015-2020))13.1.5 F. Hoffmann-La Roche Recent Development13.2 Becton13.2.1 Becton Company Details13.2.2 Becton Business Overview and Its Total Revenue13.2.3 Becton Nucleic Acid Amplification Testing Introduction13.2.4 Becton Revenue in Nucleic Acid Amplification Testing Business (2015-2020)13.2.5 Becton Recent Development13.3 Dickinson and Company13.3.1 Dickinson and Company Company Details13.3.2 Dickinson and Company Business Overview and Its Total Revenue13.3.3 Dickinson and Company Nucleic Acid Amplification Testing Introduction13.3.4 Dickinson and Company Revenue in Nucleic Acid Amplification Testing Business (2015-2020)13.3.5 Dickinson and Company Recent Development13.4 Beckman Coulter13.4.1 Beckman Coulter Company Details13.4.2 Beckman Coulter Business Overview and Its Total Revenue13.4.3 Beckman Coulter Nucleic Acid Amplification Testing Introduction13.4.4 Beckman Coulter Revenue in Nucleic Acid Amplification Testing Business (2015-2020)13.4.5 Beckman Coulter Recent Development13.5 Abbott Laboratories13.5.1 Abbott Laboratories Company Details13.5.2 Abbott Laboratories Business Overview and Its Total Revenue13.5.3 Abbott Laboratories Nucleic Acid Amplification Testing Introduction13.5.4 Abbott Laboratories Revenue in Nucleic Acid Amplification Testing Business (2015-2020)13.5.5 Abbott Laboratories Recent Development13.6 Illumina13.6.1 Illumina Company Details13.6.2 Illumina Business Overview and Its Total Revenue13.6.3 Illumina Nucleic Acid Amplification Testing Introduction13.6.4 Illumina Revenue in Nucleic Acid Amplification Testing Business (2015-2020)13.6.5 Illumina Recent Development13.7 Siemens Healthineers13.7.1 Siemens Healthineers Company Details13.7.2 Siemens Healthineers Business Overview and Its Total Revenue13.7.3 Siemens Healthineers Nucleic Acid Amplification Testing Introduction13.7.4 Siemens Healthineers Revenue in Nucleic Acid Amplification Testing Business (2015-2020)13.7.5 Siemens Healthineers Recent Development13.8 bioMerieux13.8.1 bioMerieux Company Details13.8.2 bioMerieux Business Overview and Its Total Revenue13.8.3 bioMerieux Nucleic Acid Amplification Testing Introduction13.8.4 bioMerieux Revenue in Nucleic Acid Amplification Testing Business (2015-2020)13.8.5 bioMerieux Recent Development13.9 Novartis13.9.1 Novartis Company Details13.9.2 Novartis Business Overview and Its Total Revenue13.9.3 Novartis Nucleic Acid Amplification Testing Introduction13.9.4 Novartis Revenue in Nucleic Acid Amplification Testing Business (2015-2020)13.9.5 Novartis Recent Development13.10 Bio-Rad Laboratories13.10.1 Bio-Rad Laboratories Company Details13.10.2 Bio-Rad Laboratories Business Overview and Its Total Revenue13.10.3 Bio-Rad Laboratories Nucleic Acid Amplification Testing Introduction13.10.4 Bio-Rad Laboratories Revenue in Nucleic Acid Amplification Testing Business (2015-2020)13.10.5 Bio-Rad Laboratories Recent Development 14 Analysts Viewpoints/Conclusions 15 Appendix15.1 Research Methodology15.1.1 Methodology/Research Approach15.1.2 Data Source15.2 Disclaimer15.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

See the article here:
Nucleic Acid Amplification Testing Market Research Report: Probable Key Development To Be Observed Market States And Outlook Across By 2026| F....

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Artificial Intelligence in Healthcare market.

Trusted Business Insights presents an updated and Latest Study on Artificial Intelligence in Healthcare Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Artificial Intelligence in Healthcare market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Artificial Intelligence in Healthcare Market, Market Research and Industry Forecast Report, 2019-2025 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Artificial Intelligence in Healthcare Market

The global artificial intelligence in healthcare market size was valued at USD 2.5 billion in 2018 and is anticipated to grow at a CAGR of 41.5% over the forecast period. The growing need for lowering healthcare costs, growing importance of big data in healthcare, rising adoption of precision medicine, and declining hardware costs are some factors driving growth. In addition, increasing applicability of AI-based tools in medical care and rise in venture capital investments can be attributed to the surge in demand for this technology. For instance, CarePredict, Inc. uses AI technology to monitor changes in behavior patterns and activity for early detection of health issues.Increasing number of cross-industry partnerships is expected to boost adoption of AI in the healthcare sector, which is further responsible for its lucrative growth rate. In September 2018, GNS Healthcare entered into a cross-industry partnership with Alliance and Amgen for clinical trials in oncology. The collaboration was aimed at applying data from clinical trials and Artificial Intelligence (AI) to identify factors that expedite treatment responses in metastatic Colorectal Cancer (CRC) patients. Likewise, Microsoft announced partnership with Apollo Hospitals, one of the prominent healthcare systems in India, in March 2018. The partnership is focused on developing and deploying new machine learning models for predicting the risk of developing cardiac diseases and aid doctors in treatment planning.

Number of artificial intelligence start-ups in healthcare sector has significantly grown in past few years, and the trend is expected to be the same in the coming years, which will in turn, will positively impact the market. Rise in venture capital funding in this domain is a key factor accountable for increase in the number of these start-ups. For instance, in July 2018, Kleiner Perkins and GV invested USD 21 million in Viz.ai-an AI in healthcare start-up. Similarly, HealthPlix Technologies Pvt. Ltd. raised USD 3 million in a Series A funding round led by Kalaari capital and IDG Ventures India in July 2018. Some of the prominent venture capitalist firms operating in this sector are ACCEL PARTNERS, Data Collective, General Catalyst Partners, Khosla Ventures, and others.Adoption of AI in healthcare is growing, with rise in focus on improving quality of patient care by utilizing artificial intelligence in various aspects of healthcare services, such as virtual assistants & surgeries. The AI-based tools, such as clinical decision support systems & voice recognition software, aid in streamlining workflow processes in hospitals and improving medical care, thereby enhancing patient experience.Moreover, shortage of physicians in some countries is anticipated to increase the demand for AI technology. Few companies are engaged in developing such virtual assistants. For instance, in September 2017, Nuance Communications unveiled an AI-based virtual assistance designed specifically for healthcare providers and patients. The incorporation of AI in healthcare has various benefits for both patients as well as healthcare providers. For instance, AI enables personalized care, based on health condition and past medical history. Moreover, AI-based apps can be used for continuous monitoring of health, which would in turn ensure timely care & treatment and can eventually reduce hospital stay.

Component Insights of Artificial Intelligence in Healthcare Market

Software solutions segment held the largest share in the artificial intelligence in healthcare market in 2018. The development of AI-based software solutions for healthcare is one of the key factors boosting segment growth. For instance, Nuance Communications develops a software named Dragon Medical One. According to Nuance Communications, this software can help healthcare companies as well as providers transcribe a physicians speech into an Electronic Health Record (EHR) via natural language processing. Companies such as Google, IBM, and Microsoft are develop and offer machine learning framework.Hardware segment is expected to grow with a CAGR 40.0% over the forecast period. The growing need for hardware platforms with high computing power to operate several AI-based software is one of the major factors contributing to segment growth. Processers such as ASICs, MPUs, GPUs, and FPGAs are used in AI-based platforms designed for use in healthcare.The growth of services segment can majorly be attributed to the rising need for integration and deployment of AI solutions. Moreover, the rise in adoption of AI platforms in the healthcare sector has increased the need for maintenance and support services, which are imperative to keep the devices functional.

Application Insights of Artificial Intelligence in Healthcare Market

Clinical trials emerged as the largest segment in terms of application and was valued at USD 620.5 million in 2018. Unsuccessful clinical trials generally lead to delay/failure of launch of drug candidates in the market. In order to automate clinical trial processes, pharmaceutical companies are focusing on integrating them with artificial intelligence. According to an analysis published by Accenture, the annual value for clinical trial participant identifier is estimated to reach USD 13 billion by 2026 on using this technology.

The adoption of artificial intelligence in robotic-assisted surgery platforms is anticipated to grow at significant pace and the segment is expected to show a lucrative CAGR over the forecast period. Such robots can integrate information from actual surgical experiences to form new improved insights. Such improvement is expected to enhance overall surgical outcome, thereby, enhancing consumer trust on AI integration across surgery centers. Virtual assistant is another lucrative healthcare application of AI technology. AI-enabled virtual assistant can lower the number of physician visits required by a patient, as it can assist by remotely monitoring a patients symptoms and delivering alerts to the respective healthcare professional. In addition, these virtual assistants can save about 20% of the time a nurse by omitting unnecessary visits.Regional InsightIn 2018, North America dominated the global market. Rising adoption of healthcare IT solutions, well-established healthcare sector, and availability of funding for developing AI capabilities are some of the factors contributing to the growth of the market in the region. The U.S. held the largest revenue share in North America, and is anticipated to maintain its position over the forecast period. Advancements in technology and several government initiatives are aiding adoption of digital platforms in life sciences, which can also be attributed to this share.Asia Pacific is expected to emerge as the fastest growing region. Improving infrastructure for healthcare IT, rising number of AI start-ups, and gradually increasing adoption of advanced technologies are some of the factors contributing to market growth. Rise in number of government initiatives for AI technology in this region is also expected to support growth. For instance, in March 2019, in South Korea, the Ministry of Science and ICT announced that it would initiate a trial service of an AI-based precision medicine service named Dr. Answer, in December 2019.

Market Share Insights of Artificial Intelligence in Healthcare Market

IBM Corporation; NVIDIA Corporation; Nuance Communications, Inc.; Microsoft; Intel Corporation; and DeepMind Technologies Limited are among the major players. Investments in R&D, collaborations with other industry participants, and service differentiation are among the key strategies adopted by these players for gaining a competitive edge. For instance, in February 2019, IBM Corporation announced a 10-year partnerships, including an investment of USD 50 million in AI research, with Vanderbilt University Medical Center and Brigham and Womens Hospital.

p2 Segments covered in the reportThis report forecasts revenue growth at global, regional, & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, this market research report has segmented global artificial intelligence in healthcare market report on the basis of component, application, and region:

Component Outlook (Revenue, USD Million, 2019 2030)

Software Solutions

Hardware

Services

Application Outlook (Revenue, USD Million, 2019 2030)

Robot-assisted Surgery

Virtual Assistants

Administrative Workflow Assistants

Connected Machines

Diagnosis

Clinical Trials

Fraud Detection

Cybersecurity

Dosage Error Reduction

Quick Read Table of Contents of this Report @ Artificial Intelligence in Healthcare Market, Market Research and Industry Forecast Report, 2019-2025 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Originally posted here:
Artificial Intelligence in Healthcare MARKET REPORT 2020 TO 2028 MARKET ANALYSIS, SIZE, SHARE, TRENDS, KEY PLAYERS, DRIVERS AND FORECAST - Cole of...

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Clinical Oncology Next Generation Sequencing market.

Trusted Business Insights presents an updated and Latest Study on Clinical Oncology Next Generation Sequencing Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Clinical Oncology Next Generation Sequencing market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Clinical Oncology Next Generation Sequencing Market Size Report 2025 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Clinical Oncology Next Generation Sequencing Market

The global clinical oncology next generation sequencing market size was estimated at USD 627.2 million in 2018. Significant increase in the adoption of genome-focused pharmacology for cancer treatment is expected to provide growth avenues for the market. NGS serves as one of the highly advanced genomic techniques for the analysis of mutations that lead to cancer progression.The growth of the market is supplemented by decrease in the cost of genetic sequencing, advancements in the field of personalized medicine and oncology, rise in prevalence of cancer, globally, and increase in adoption of this technique over single-gene testing. Since this technique is more reliable than Sanger sequencing for diagnosis, the market is expected to witness substantial growth over the forecast period.

Breakthrough advancements in the development of genetic-based tests for oncology and other disorders during the past few years have significantly propelled market growth. Next generation sequencing technology offers a better understanding of tumor mechanism, thus enabling rational drug design. As a result, more products are expected to get commercialized in the near future.A rise in oncology-related spending is further expected to fuel market growth in the coming years. Government organizations are focused on encouraging patients to regularly undergo diagnostic examinations to reduce oncology-related healthcare expenditures. As per data estimates, healthcare expenditure is anticipated to rise significantly, thereby influencing the adoption of NGS diagnostics platforms.The biotechnology industry is marked by high competition and so is the NGS market for clinical as well as research applications. Prominent participants are actively involved in R&D to develop novel rapid, small, and less expensive platforms. Service providers are embracing the trend of increasing the amount of constructed sequence reads for each cycle run.Commercially available sequencing platforms analyze both DNA and RNA samples. Key players aim to increase the utility of high throughput technologies for clinical applications. The acquisition of smaller entities operating in the market is also one of the strategic initiatives adopted by players to maintain a competitive position. For instance, in May 2018, Illumina acquired Edico Genome to accelerate data analysis for its next generation sequencing platforms.

Technology Insights of Clinical Oncology Next Generation Sequencing Market

Targeted sequencing in clinical oncology accounted for the largest revenue share in 2018 and is expected to maintain its share over the forecast period. Targeted sequencing and resequencing encompasses shortest read lengths and is one of the conventional forms of commercially available sequencing technology. Moreover, focused panels for targeted cancer sequencing aid in the reduction of cost burdens owing to reduction in the amount of data to be analyzed. As targeted cancer sequencing evaluates a limited gene-set, it can be used to analyze variations in rare tumor sub-clones with greater sensitivity and deep coverage.The whole-genome sequencing segment is expected to grow at the fastest rate through 2025. Application of whole genome sequencing technology for comparisons between tumor tissue and normal tissue in clinical oncology is attributive to segment growth. Developed rapid, large-capacity sequencers such as HiSeq and MiSeq series find application in largescale whole genome sequencing.Workflow InsightsNGS workflow includes library preparation, sample enrichment, sample quality assurance, DNA tagging, sequencing, DNA quantification, genetic data assemble, data storage and analysis, and interpretation. Sequencing accounted for the largest share in the clinical oncology NGS market as it is the most important and crucial step in the entire process and involves the usage of sophisticated platforms. Continuous R&D has led to the introduction of novel, benchtop, or portable NGS sequencing platforms, thereby complimenting market growth. Moreover, NGS platforms are expected to witness lucrative growth throughout the forecast period owing to the expected increase in adoption and usage rates of whole-genome sequencing.

Application Insights of Clinical Oncology Next Generation Sequencing Market

Next generation sequencing finds application in the field of clinical oncology for screening, companion diagnostics, and others. The adoption of NGS-based molecular diagnosis for oncology has increased as this technology allows concurrent sequencing of several target genes and provides rich diagnostic markers for the development of molecular diagnostic assays.Application of NGS technology in the field of oncology ensures early diagnosis so that treatment measures can be taken in time. Therefore, the arrival of NGS for cancer diagnosis has opened many new frontiers in the field. For instance, large-scale projects such as International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA) have issued data from thousands of tumors across major cancer types. This data can be used to have a comprehensive overview of cancerous cells and help enhance prognostic and therapeutic applications.The market for companion diagnostics is expected to grow significantly in the coming years owing to numerous benefits offered by the technique in the field of oncology. Currently, available companion diagnostic products are applicable for non-small cell lung cancer, melanoma, colorectal, ovarian, and breast cancers.End-use InsightsBy way of end use, the clinical oncology next generation sequencingmarket has been segmented into hospitals, clinics, and laboratories. Laboratories held a prominent share in the market for clinical oncology NGS and this trend is likely to continue over the forecast period. The hospitals segment is expected to register a significant CAGR through 2025. Rise in adoption of NGS services in hospitals to determine the rate of disease progression and scale-up the appropriate treatment regimen for cancer is anticipated to influence growth in this segment.

Provision of clinical services by leading players in the market such as Illumina, which includes CLIA certified tests for predisposition screening, is anticipated to boost revenue in the coming years. Clinics utilize NGS technology to identify novel cancer mutations, for genetic testing for hereditary cancer syndrome, for personalized oncology treatment, and for detection of circulating DNA for cancer.

Regional Insights of Clinical Oncology Next Generation Sequencing Market

North America occupied the largest share in the global market in 2018 owing to increased focus of government bodies on cancer treatment, rise in healthcare expenditure, and presence of adequate healthcare infrastructure. Moreover, high prevalence of cancer, growing demand for personalized medicine, well-developed healthcare facilities, and availability of novel diagnostics techniques, especially in the field of oncology, can be attributed to the estimated market share of the region. Additionally, growing morbidity and mortality due to cancer has increased the need for development of novel therapies, thereby driving this regional market.Asia Pacific is expected to be the fastest-growing region throughout the forecast period majorly due to continuous reforms in the healthcare and pharmaceutical industries in the region. Other factors contributing to this growth are untapped markets in emerging economies. The market is continuously driven by rise in cancer incidence across Asia Pacific. China dominates the cancer burden in the region, followed by India, Japan, Indonesia, and the Republic of Korea. The top three types of cancer with his incidences in the region are breast, lung, and prostate cancer.

Market Share Insights of Clinical Oncology Next Generation Sequencing Market

The global market is marked by the presence of high competition among market players. Illumina and Roche account for a substantial share owing to wide product offerings in the field of next-generation sequencing for cancer. Other prominent players operating in this market space include Agilent; Thermo Fisher Scientific; Myriad Genetics; Beijing Genomics Institute (BGI); Perkin Elmer, Inc.; Qiagen NV; Partek, Inc.; Pacific Bioscience, Inc.; Foundation Medicine; Oxford Nanopore Technologies Ltd.; Paradigm Diagnostics, Inc.; Caris Life Sciences; and Eurofins Scientific.

Segmentations, Sub Segmentations, CAGR, & High-Level Analysis overview of Clinical Oncology Next Generation Sequencing Market Research ReportThis report forecasts revenue growth at global, regional, and country levels and provides an analysis of latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, this market research report has segmented the globalclinical oncology next generation sequencing market report on the basis of technology, workflow, application, end use, and region:

Technology Outlook (Revenue, USD Million, 2019 2030)

Whole Genome Sequencing

Whole Exome Sequencing

Targeted Sequencing & Resequencing

Workflow Outlook (Revenue, USD Million, 2019 2030)

NGS Pre-Sequencing

NGS Sequencing

NGS Data Analysis

Application Outlook (Revenue, USD Million, 2019 2030)

Screening

Sporadic Cancer

Inherited Cancer

Companion Diagnostics

Others

End-use Outlook (Revenue, USD Million, 2019 2030)

Hospitals

Clinics

Laboratories

Quick Read Table of Contents of this Report @ Clinical Oncology Next Generation Sequencing Market Size Report 2025 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Originally posted here:
How COVID-19 Pandemic Will Impact Clinical Oncology Next Generation Sequencing Market Business Opportunity, And Growth 2020-2026 - Cole of Duty

Diabetes has assumed epidemic proportions today and millions of people suffer from this condition globally. There may be many causes behind this problem like family history, unhealthy diet and a sedentary lifestyle. Some environmental pollutants may also trigger this condition. It often brings with it many complications like blurry vision, weight loss and excessive thirst. Uncontrolled blood sugar levels over time can result in serious health issues like kidney problems and diabetic retinopathy. Also Read - Diabetes increases your risk of cancer: Experts blame DNA damage

If you have diabetes, you need to take good care of your feet. This is because one of the complications of this condition is diabetic neuropathy. It leads to loss of sensation in your feet and you may be unaware if you have any injury. This happens because fluctuation in blood sugar levels may damage the nerves and vessels of the feet. Unattended injuries can cause gangrene and it may result in loss of a limb. In fact, diabetic neuropathy is the leading cause of amputations in people with diabetes. Also Read - Know how to deal with wounds if you have diabetes

This complication of diabetes may develop over time and you may not notice it immediately. Some people experience a feeling of thickness on their soles. At times, you may also develop open sores and calluses on your soles. If you have an injury, it will take a longer time to heal. A burning sensation on the feet and extreme sensitivity may also be symptoms of diabetic neuropathy. Also Read - Diabetes alert: Beware of dementia and cancer if you have elevated blood sugar levels

If you have this condition, you must be extra careful when it comes to your feet. If you notice any changes in the shape of your feet or any injury that is not healing, seek immediate medical help. This will help you save your feet. One important thing that you need to do is wear the right shoes. There are now many shoes that are especially designed for people with diabetes. These special shoes are deeper than normal shoes. Choose something that is comfortable and fits you well. Make sure that you can wriggle your toes around after wearing your shoes. Avoid wearing heels and fancy open-toed ones. Straps are bad too as it may sometimes cut into your skin and injure you.

Tip: Shop for footwear at the end of the day when your feet may be slightly swollen. This will help you pick a pair that will not be tight around this time of the day.

You can also ask your doctor about wearing compression socks to stimulate circulation in your lower limbs. Other than this, be gentle with your feet and treat them with love and care. Every night before going to bed, make it a point to check your feet properly for any sings of injury. If you notice anything different, get an appointment with your doctor. Be sure to keep your nails trimmed and groomed. You may also give yourself a regular pedicure and use scrubs to exfoliate your feet at frequent intervals. Be sure to wash your feet with warm water before going to bed every night. This night time ritual will go a long way in keeping your feet safe.

Published : June 29, 2020 7:08 pm

Visit link:
Save your feet from diabetic neuropathy: A few tips to keep your feet healthy - TheHealthSite

Systemic lupus erythematosus (SLE) may have an early effect on peripheral nerve function before the development of electrophysiologic or clinical neuropathy, according to study results published in Rheumatology International.

Researchers evaluated data from nerve conduction studies (NCS) in patients with SLE without clinical or electrophysiologic neuropathy and healthy control participants matched by age and sex. Data included sensory nerve action potential (SNAP), sensory nerve conduction velocities, (SNCV), and demographics. Investigators aimed to determine whether SLE could have an even earlier effect on peripheral nerve function before the development of electrophysiologic abnormalities.

A total of 61 patients with SLE without electrophysiologic neuropathy (88.5% women; median disease duration, 8 years) were included in the study. Patients had a median SLE Disease Activity Index (SLEDAI) score of 3 (range, 0-16). A total of 49.2% of patients had mild disease activity (score, 1-5), and 32.8% showed no active disease (score, 0).

Although NCS results were within the normal range, the researchers found statistically significant differences in several motor and sensory parameters between the patient and control group. Compared with control participants, among patients with SLE, distal compound muscle action potential was significantly lower in the ulnar, fibular, and posterior tibial nerves and motor nerve conduction velocities were significantly slower in the median, ulnar, and fibular nerves. In the sensory NCS, patients with SLE vs control participants showed significantly lower SNAP amplitudes in the sural nerves and slower SNCV in the median, ulnar, and sural nerves. Patients with SLE also had longer minimum F-wave latencies and their H reflexes more frequently absent.

No significant correlations were found between NCS parameters and SLEDAI or disease duration among patients with SLE; however, there were correlations between disease relapses and motor conduction velocities, specifically of the tibial and fibular nerves (r=-0.315; P =.013 and r=-0.426; P =.001).

Researchers noted that NCS measure the function of only large nerve fibers, which may represent a limitation of the study, because small peripheral nerve fibers have also been recognized to be involved in SLE.

Overall, despite having NCS results within a normal range, the data show that patients with SLE without other known causes of neuropathy experienced worse peripheral nerve function. This could suggest that SLE has early negative effects on peripheral nerve function, which supports the possibility that SLE polyneuropathy may gradually progress to development of clinical peripheral neuropathy.

Reference

Fong S-Y, Raja J, Wong K-T, Goh K-J. Systemic lupus erythematosus may have an early effect on peripheral nerve function in patients without clinical or electrophysiological neuropathy: comparison with age- and gender-matched controls [published online June 2, 2020]. Rheumatol Int. doi:10.1007/s00296-020-04610-8

Read more:
SLE May Have Early Effect on Peripheral Nerve Function Before Electrophysiologic or Clinical Neuropathy Development - Rheumatology Advisor

The recent research report titledGlobalNeuropathy Pain TreatmentMarket Report 2020, Forecast to 2025sheds light on critical aspects of the market by compiling the historical, current, and future outlook of the market and the factors responsible for such growth. The report contains numerical data and certified data, which is gathered from certified sources and market experts. The document offers useful guidelines for players to understand and define their strategies more efficiently in order to assist them to stay ahead of their competitors. The report includes and evaluates all the changes and shifts that are observed in the globalNeuropathy Pain Treatmentmarket. It encompasses data that is derived from historical trends and present market scenarios.

Get Free Sample Report:https://www.magnifierresearch.com/report-detail/39757/request-sample

The report then delivers information on key segmentation of the globalNeuropathy Pain Treatmentmarket including type/product, application, and geography (country/region). All segments are investigated in relation to different factors such as market size, market share, value, growth rate, other quantitative information, and forecast for 2020 to 2025 time period. The report explains market dynamics in the most detailed and easiest possible manner. Mainly, the current and future trends of the market along with opportunities for the new players who are in the process of entering the global market are highlighted in the report. It enlightens crucial details sales, product descriptions, individual market standing, pictorial representation of statistical data, and contact information of the leading companies.

Market By Companies:

The analysts have profiled leading players of the globalNeuropathy Pain Treatmentmarket, keeping in view their recent developments, market share, sales, revenue, areas covered, product portfolios, and other aspects. The report attempts its aim to present the key manufacturers, presenting the sales, revenue, market share, and recent development for key players. The manufacturing cost structure encompasses details about the raw material, manufacturing process analysis, as well as labor costs. Overall, this section lists companies operating in every region, the prevalent competitive landscape and intensity map of key players presence in each region.

In the global market, the following companies are covered:Pfizer, Depomed, Eli Lilly, Endo, Grnenthal Group

Geographically, this report is segmented into different chief territories, containing profits, sales, growth rate and market share (percent) ofNeuropathy Pain Treatmentin the areas listed below:North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, Colombia etc.), Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Access Full Report:https://www.magnifierresearch.com/report/global-neuropathy-pain-treatment-market-report-2020-forecast-39757.html

Pivotal Highlights of Market:

Customization of the Report:This report can be customized to meet the clients requirements. Please connect with our sales team (sales@magnifierresearch.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Magnifier Research is a leading market intelligence company that sells reports of top publishers in the technology industry. Our extensive research reports cover detailed market assessments that include major technological improvements in the industry. Magnifier Research also specializes in analyzing hi-tech systems and current processing systems in its expertise. We have a team of experts that compile precise research reports and actively advise top companies to improve their existing processes. Our experts have extensive experience in the topics that they cover. Magnifier Research provides you the full spectrum of services related to market research, and corroborate with the clients to increase the revenue stream, and address process gaps.

Contact UsMark StoneHead of Business DevelopmentPhone:+1-201-465-4211Email:sales@magnifierresearch.comWeb:www.magnifierresearch.com

Here is the original post:
Global Neuropathy Pain Treatment Market 2020 Overview with (Covid-19) Impact Analysis of Growth, Competitive landscape and Forecast 2025 - Bandera...

By Pat Anson, PNN Editor

Low level light therapy (LLLT) also known as laser therapy has been touted for years as a treatment for arthritis, neck and back pain, fibromyalgia, neuropathy and even spinal cord injuries.

But in the first case of its kind, the Federal Trade Commission is going to court to get the makers of a light therapy device called the Willow Curve to stop making deceptive claims that it can treat chronic pain.

When LLLT sellers say their devices will relieve pain, theyd better have the scientific proof to back it up, Andrew Smith, Director of the FTCs Bureau of Consumer Protection, said in a statement. People looking for drug-free pain relief deserve truthful information about these products.

In a complaint filed in federal court against the inventors and marketers of the Willow Curve, the FTC alleges that Dr. Ronald Shapiro and David Sutton personally made deceptive claims about the health benefits of the device and falsely claimed it was approved by the Food and Drug Administration to treat chronic pain, severe pain and inflammation.

Willow Curve is a curved plastic device that delivers low-level light and mild heat to painful areas. Its been sold online and through retailers and healthcare professionals since 2014, most recently at a price of $799.

In a 2016 commercial, television personality Chuck Woolery said the Willow Curve offers drug free pain relief for the digital age and personally promised that the Curve could change your life.

View post:
FTC Takes Dim View of Light Therapy Device - Pain News Network

It is hard to remember what science was like beforehand

Jun 27th 2020

TWENTY YEARS ago, on June 26th 2000, those running the public Human Genome Project and its private-sector shadow, a firm called Celera Genomics, decided to declare victory. In a simultaneous breasting of the tape, each published a working draft of the genome. The broker, Bill Clinton, hosted the chief scientists at the White House. Hyperbolic comparisons were made to the Apollo project to land people on the Moon.

Unlike Apollo, though, this announcement marked a beginning rather than an end. Genomics is now so embedded in biology that it is hard to recall what things were like before it. Those first human sequences cost billions of dollars to obtain. Today, with the advent of new technologies, a full sequence costs about $200, and less detailed versions are cheaper still. It is as if, to use Apollo as the analogy, regular shuttles to the Moon had become available at prices an average family in the West could affordand the more adventurous might now be considering a trip to Mars.

Researchers with a hypothesis to test can, for instance, turn to biobanks containing details of tens or hundreds of thousands of peopletheir medical records, education, employment and, crucially, data about their genomes. Private companies will also sequence genomes to varying standards, for a suitable price. It is probably the case, and if not, it soon will be, that more than 1m human genomes have been sequenced by one method or another.

Genomics also helps non-medical biology. Many non-human species, including crops and domestic animals, have had their genomes sequenced. Though tinkering directly with the genes of organisms that end up on peoples plates still makes some a bit queasy, that is increasingly unnecessary. Genomic knowledge can now be used to speed up selective breeding, without the need for genetic engineering.

At the other end of the scientific spectrum, what can be done for Homo sapiens can be done, using DNA from fossils, for other (now extinct) species of human being: the Neanderthals and Denisovans. There is a possible practical interest even here. Sequencing shows that these species once interbred with Homo sapiens. It also suggests that the traces of that interbreeding which remain may help the recipient to fight off infections, by combating viruses and boosting the immune system.

Sources: INSDC; NHGRI; Broad Institute; S. Peyrgne et al., Science Advances, 2019; S. Mallick et al., Nature, 2016

This article appeared in the Graphic detail section of the print edition under the headline "Dawn of an era"

Read the original post:
The Human Genome Project transformed biology and medicine - The Economist

Longer life-expectancy is a cumulative effect of a healthy lifestyle and favorable environmental conditions. A trend of continuously increasing life expectancy has been a witness since a decade, primarily because of advances in medical sciences and treatment of chronic life-threatening diseases, availability of clean water and environment and other factors. This trend is projected to further show even more exponential growth graph owing to the anti-aging medicines, stem cell therapeutics, genetic screening and interventions, and high-tech biomedicines. American Academy of Anti-Aging Medicine claimed that anti-aging medicines can add up to 10-20 years to the life expectancy of a human. Today, a combination of calorie-restricted diet, regular exercise, and anti-aging medicines are claimed to slow the process of senescence and aging. Various medicines used against the treatment of acute or chronic diseases can be considered as anti-aging medicines, however, to define anti-aging medicine market we have considered only the drugs that are directly prescribed and used for delaying the effects of aging.

Get Free Sample Copy With Impact Analysis Of COVID-19 Of Market Report @https://www.persistencemarketresearch.com/samples/26233

The constantly growing demand to look young in old individuals and to remain young and youthful in young people drive the anti-aging market. The influence of aesthetics from the fashion and television industry propel the demand to retain the features and energy of younger age in old people. Additionally, the increasing number of anti-aging medicine manufacturers in the decade contribute to higher availability of the anti-aging medicine resulting in expansion of the global anti-aging medicine market. However, skeptical approach to anti-aging medicine as being an external stimulator of cell-cycles is a restraint to the expansion of anti-aging medicine market.

The global Anti-aging medicine market is segmented on basis of product type, age group, distribution channel, and region:

The rising demand for beauty consciousness amongst people and the desire to stay young is the primary factor fueling the growth of anti-aging medicines in the market. The acclaimed benefits of the products and affordability along with regional presence compel the demand for anti-aging medicine in the global market. Hormonal replacement therapy segment in product type is expected to account maximum market share in the terms of revenue in the global anti-aging medicine market. However, antioxidant therapy segment in product type is expected to grow with the highest CAGR over the forecast years owing to the rising awareness about the plethora of benefits of antioxidants in anti-aging among the public. On the basis of the route of administration, the global anti-aging medicine market is segmented as oral, injectable and topical, out of which oral segment is expected to generate maximum revenue share over the forecast period. As per the distribution channel, the global anti-aging medicine market is segmented as hospital pharmacies, retail pharmacies, e-commerce, and drug stores. The e-commerce segment in the distribution channel is estimated to grow with the highest CAGR over the forecast time.

Regionally, the global anti-aging medicine market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America anti-aging medicine market is projected to account for the largest market share in the terms of revenue in the global anti-aging medicine market owing to the higher healthcare expenditure and presence of numerous manufacturers.

You Can Buy This PMR Healthcare Report From Here @https://www.persistencemarketresearch.com/checkout/26233

Europe is expected to hold the second largest share in the global anti-aging medicine market during the forecast period because of the growing geriatric population and higher spending on healthcare products and supplements. MEA anti-aging medicine market is expected to witness sluggish growth over the forecast time owing to the limited presence of manufacturers and lower healthcare expenditure. Asia Pacific is projected to grow with the highest CAGR over the forecast years in the global anti-aging medicine market due to higher demand from end users and regional penetration of the key players in the region.

Some of the players operating in the global anti-aging medicine market are Pfizer, Evolution GmbH, Himalaya Global Holdings Ltd., Cipla Limited, Mylan Laboratories, Novartis, Merck Group, Vitabiotics, William Ransom & Son Holdings Plc, Uni-Vite Healthcare and Health Made Easy Limited amongst others.

Read more:
Key End use Industries to Surge Sales of Anti-Aging Medicine During the COVID 19 pandemic - 3rd Watch News

Boca Raton, FL, June 29 Human leukocyte antigens (HLA) diverse genetic markers on our cells that help match patients and donors for bone marrow transplant are the focus of a new study led by the Gift of Life Marrow Registry.

The study, in collaboration with researchers at Rutgers Cancer Institute of New Jersey and the genetic crowd science portal Root, aims to help answer a key question: why do some people get COVID19 or particular symptoms, while others avoid them? More than 350,000 donors in Gift of Life's registry have been invited to participate, helping researchers answer this important question.

"Every volunteer donor is already HLA-typed, presenting a tremendous opportunity to drive broader science through the prism of these immune-related genes," said Gift of Life's Founder and CEO Jay Feinberg. "We're excited to help the world understand how our immune systems may shape the pandemic."

"We hope to learn whether immune-vital tissue match genes such as HLA help explain why some of us avoid COVID-19, while others get severe symptoms or need particular treatments," said the study's principal investigator Jeffrey Rosenfeld, PhD, Assistant Professor of Pathology and Laboratory Medicine, Rutgers Robert Wood Johnson Medical School. "Adding such key data to the fight against COVID-19, we can help solve the mystery of why it affects different people so differently."

Subscribe

Root's founder, geneticist Nathaniel Pearson, PhD, noted that "because transplant registries read HLA genes better than consumer DNA tests do, a study like this can best reveal how these diverse, immune-vital genes may shape COVID-19. Gift of Life members, who have long saved lives via transplants, now show us how everyday people can help the world beat a pandemic too."

Participants can also opt into short monthly surveys for the coming year, even if they have never had COVID-19. The researchers will study their de-identified data, to better understand how tissue match genes and other factors may figure in COVID-19 risks and outcomes.

Subscribe

The new study furthers Gift of Life's efforts to help people and communities in need during the pandemic. The organization has increased capacity at the Dr. Miriam and Sheldon G. Adelson Gift of LifeBe The Match Collection Center to become a non-hospital based go-to for stem cell donations and contributed 10,000 specialized swabs to Baptist Health South Florida via Boca Raton Regional Hospital to be used for COVID-19 testing.

About Gift of Life Marrow RegistryThe Gift of Life Marrow Registry is a 501(c)(3) nonprofit organization headquartered in Boca Raton, Fla. The organization, established in 1991, is dedicated to saving lives by facilitating bone marrow and blood stem cell transplants for patients with leukemia, lymphoma, and other blood-related diseases. To learn more about Gift of Life or to make a tax-deductible donation, visit http://www.giftoflife.org.

About Rutgers Cancer Institute of New JerseyAs New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center, Rutgers Cancer Institute, along with its partner RWJBarnabas Health, offers the most advanced cancer treatment options including bone marrow transplantation, proton therapy, CAR T-cell therapy and complex robotic surgery. Along with clinical trials and novel therapeutics such as precision medicine and immunotherapy many of which are not widely available patients have access to these cutting-edge therapies at Rutgers Cancer Institute of New Jersey in New Brunswick, Rutgers Cancer Institute of New Jersey at University Hospital in Newark, as well as through RWJBarnabas Health facilities.

Along with world-class treatment, which is often fueled by on-site research conducted in Rutgers Cancer Institute laboratories, patients and their families also can seek cancer preventative services and education resources throughout the Rutgers Cancer Institute and RWJBarnabas Health footprint statewide. To make a tax-deductible gift to support the Cancer Institute of New Jersey, call 848-932-8013 or visit http://www.cinj.org/giving.

About Root

Root (rootdeep.com) works to grow, diversify, and engage the ranks of blood and marrow volunteers earth's biggest group of living, contactable DNA data owners to save patients in need, honor their good will with good insights, and empower them to spark broader health science discoveries with researchers.

Continue reading here:
Gift of Life, Root and Rutgers Researchers Launch COVID-19 Study - Patch.com

29 June 2020

There may be at least two different biologically relevant subtypes of polycystic ovary syndrome (PCOS).

By comparing the genomes of 893 women of European ancestry diagnosed with PCOS, researchers found that these women could be grouped into at least two distinct subsets, which are associated with novel gene regions and which have different biological responses.

'We're starting to make headway on what causes PCOS. It's very frustrating for patients because it's poorly understood and patients often see several physicians before PCOS is diagnosed,' said senior author Dr Andrea Dunaif. 'Through genetics, we're beginning to understand the condition and may have specific targeted therapies in the not-too-distant future.'

PCOS is an infertility disorder that affects at least 15 percent of women of reproductive age. The cause of PCOS is unknown, but it does appear to run in families, suggesting a genetic basis to the disorder. PCOS is currently diagnosed based upon physical features and symptoms, including irregular or missing periods, raised levels of male sex hormones, hirsutism and small cysts on the surface of the ovaries.

There is a variation of symptoms among PCOS patients and this study, conducted by scientists at the Mount Sinai Health System in New York, aimed to discover whether there were any genetic, clinical or biochemical differences that could explain this.

Dr Dunaif and her team identified PCOS subtypes by classifying cases into relative groups called clusters from the results of their previously published PCOS genome-wide association study (GWAS). The clusters were then repeated in an independent group of 263 PCOS cases and the researchers identified two distinct PCOS subtypes: a 'reproductive' group and a 'metabolic' group.

Women in the 'reproductive' group (approximately 23 percent of cases) had raised levels of luteinising hormone (LH), which triggers ovulation, and higher sex hormone-binding globulin (SHBG) levels, a protein that regulates the ability of testosterone to enter its target tissues. In addition, this group had lower insulin levels and a lower body mass index (BMI).

Women in the 'metabolic' group (approximately 37 percent of cases) had raised levels of glucose and insulin and a higher BMI. They also had lower LH and SHBG levels.

The remaining women (approximately 40 percent of cases) had no distinguishable characteristics, with traits of both the metabolic and reproductive subgroups.

The researchers discovered that the subtypes tended to cluster in families and that carriers of rare genetic variants in DENND1A, a gene involved in male hormone production, were more likely to have the reproductive subtype of PCOS.

Rather than a catch-all approach for PCOS patients, the researchers suggest that these distinct forms may benefit from different treatment approaches, as they are underpinned by different biological mechanisms, and this could improve long-term outcomes for patients.

'In contrast to classifying disorders based on expert opinion, this is a very powerful objective approach to categorising syndromes like PCOS into distinct subtypes with different causes, treatment and clinical outcomes, said Dr Dunaif.

This study was published in PLOS Medicine.

Original post:
Polycystic ovary syndrome may have more than two different subtypes - BioNews

New York City, United States The effect of the coronavirus pandemic and the lockdown it activated is unmistakably obvious in budgetary markets. Yet, there is still no clearness on the more profound effect that it is having across organizations and modern areas. In view of evaluations made by various examiners and industry body Ficci, here is an effect investigation in human services area.

Spinal Cord Trauma Treatment Market: Global Industry Analysis 2012 2016 and Forecast 2017 2025is the recent report of Persistence Market Research that throws light on the overall market scenario during the period of eight years, i.e. 2017-2025. According to this report, Globalspinal cord trauma treatment marketis expected to witness significant growth during the forecast period.

This growth is expected to be primarily driven by increasing incidence of spinal cord trauma, and increasing government support to reduce the burden of spinal cord injuries. Additionally, development of nerve cells growth therapy is expected to boost the market in near future.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/17353

Company Profiles

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/17353

The global market for spinal cord trauma treatment is is estimated to be valued at US$ 2,276.3 Mn in terms of value by the end of 2017. The global spinal cord trauma treatment market is expected to expand at a CAGR of 3.7% over the forecast period to reach a value of US$ 3,036.2 Mn by 2025end.

Global Spinal Cord Trauma Treatment Market: Trends

Global Spinal Cord Trauma Treatment Market: Forecast by End User

On the basis of end user, the global spinal cord trauma treatment market is segmented into hospitals and trauma centers. Hospitals segment dominated the global spinal cord trauma treatment market in revenue terms in 2016 and is projected to continue to do so throughout the forecast period.

Hospitals and trauma centers segments are expected to approximately similar attractive index. Hospitals segment accounted for 53.2% value share in 2017 and is projected to account for 52.5% share by 2025 end.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/17353

Global Spinal Cord Trauma Treatment Market: Forecast by Injury Type

On the basis of injury type, the global spinal cord trauma treatment market is segmented into complete spinal cord injuries and partial spinal cord injuries.

Partial spinal cord trauma treatment segment is expected to show better growth than the completed spinal cord treatment segment due to higher growth in the incidence rate of partial spinal cord trauma than the complete spinal cord trauma. With US$ 1,870.3 Mn market value in 2025, this segment is likely to expand at CAGR 3.8% throughout the projected period.

Global Spinal Cord Trauma Treatment Market: Forecast by Treatment Type

On the basis of treatment type, the global spinal cord trauma treatment market is segmented into corticosteroid, surgery, and spinal traction segments.

Surgery segment dominated the global spinal cord trauma treatment market in revenue terms in 2016 and is projected to continue to do so throughout the forecast period. Surgery segment is the most attractive segment, with attractiveness index of 2.6 over the forecast period.

Global Spinal Cord Trauma Treatment Market: Forecast by Region

This market is segmented into five regions such as North America, Latin America, Europe, APAC and MEA. Asia-Pacific account for the largest market share in the global spinal cord trauma treatment market.

Large patient population due to the high rate of road accidents and crime is making the Asia Pacific region most attractive market for spinal cord trauma treatment. On the other hand, MEA and Latin America is expected to be the least attractive market for spinal cord trauma treatment, with attractiveness index of 0.3 and 0.5 respectively over the forecast period.

Report Highlights:

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Feminine Hygiene Product Market Feminine Hygiene Products Market Segmented By Sanitary Pads/Napkins, Tampons, Panty Liners, Menstrual Cups, and Feminine Hygiene Wash.For More Information

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics andmarket research methodologyto help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish KoltePersistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Websitehttps://www.persistencemarketresearch.com

Excerpt from:
Spinal Cord Trauma Treatment Market Size : Technological Advancement and Growth Analysis with Forecast to 2025 - 3rd Watch News

Understanding gestational diabetes

Gestational diabetes can be a scary diagnosis, but like other forms of diabetes, its one that you can manage. It doesnt mean that you had diabetes before you conceived or that you will have diabetes after you give birth. It means that, by working with your doctor, you can have a healthy pregnancy and a healthy baby. No matter what, know that you have all the support you need for both you and your baby to be at your best.

We dont know what causes gestational diabetes, but we know that you are not alone. It happens to millions of women. We do know that the placenta supports the baby as it grows. Sometimes, these hormones also block the action of the mothers insulin to her body and it causes a problem called insulin resistance. This insulin resistance makes it hard for the mothers body to use insulin. And this means that she may need up to three times as much insulin to compensate.

The key to treating it is to act quicklybecause as treatable as it is, gestational diabetes can hurt you and your baby. Work with your doctor to keep your blood sugar levels normal, through special meal plans and regular physical activity. Your treatment may also include daily blood sugartesting and insulin injections.

Read more on gestational diabetes

In addition to type 1, type 2 and gestational diabetes, a small minority of people develop specific types of diabetes due to other causes. This includes:

Because these types of diabetes are rare, they are often misdiagnosed as other types of diabetes. You can learn more about these types of diabetes in the Classification and Diagnosis of Diabetes section in the Standards of Medical Care in Diabetes. If you think you might have one of these types, be sure to talk with your doctor.

More on diabetes from other causes

When it comes to prediabetes, there are no clear symptomsso you may have it and not know it. Heres why thats important: before people develop type 2 diabetes, they almost always have prediabetesblood sugar levels that are higher than normal but not yet high enough to be diagnosed as diabetes. You may have some of the symptoms of diabetes or even some of the complications.

Read more:
Diabetes Overview - Symptoms, Causes, Treatment

China releases genome of latest viral outbreak in Beijing

China has released genome sequencing data from samples taken in Beijing, amid the latest outbreak in the capital.

Virus genome sequencing is a vital and rapidly-developing tool in the diagnosis of COVID-19 and in understanding the spread and control of the new coronavirus as it moves around the globe.

The latest genome sequencing which has been shared with the World Health Organization (WHO) and the Global Influenza Data Initiative (GISAID) has identified a European strain of the virus, according to Chinese officials. But the WHO said that further investigation was needed to understand the origin of the latest outbreak.

Evidence suggests coronavirus might trigger diabetes

Diabetes is a known risk factor for developing severe COVID-19 and people with the condition are more likely to die. Now, some researchers are also pursuing the idea that diabetes doesnt just make people more vulnerable to the coronavirus, but that the virus might also trigger diabetes in some.

Early evidence from tissue studies and some people with COVID-19 shows that the new coronavirus damages insulin-producing cells, which are important for regulating blood sugar levels.

A handful of COVID-19 patients have spontaneously developed diabetes and dozens more have arrived in hospital with extremely high levels of blood sugar and ketones, which are produced from fatty deposits in the liver. When the body doesnt make enough insulin to break down sugar, it uses ketones as an alternative source of fuel.

New findings from experiments on miniature lab-grown pancreases also suggest that the virus might trigger diabetes by damaging insulin-producing cells.

However, in order to prove a causal link between the virus and the onset of diabetes, researchers will need to conduct well-constructed epidemiological cohort studies as well as further lab experiments.

Young people shielded from infection by close contacts

People under the age of 20 are much less likely than their elders to catch the new coronavirus from an infected household member, according to new research led by scientists at the University of Florida and the Center for Disease Control and Prevention in China.

The team analysed viral transmission between infected people in the city of Guangzhou in China and those whod had close contact with them. After public-health officials enforced isolation of infected individuals and quarantine of their contacts, people under the age of 20 had a 5.2% risk of being infected by a member of their household, compared with a 14.8% risk for people aged 2059 and an 18.4% risk for people aged 60 and above.

The researchers also found that people with COVID-19 were at least as infectious before their symptoms started as after, adding to the evidence of asymptomatic and pre-symptomatic viral spread.

The first global pandemic in more than 100 years, COVID-19 has spread throughout the world at an unprecedented speed. At the time of writing, 4.5 million cases have been confirmed and more than 300,000 people have died due to the virus.

As countries seek to recover, some of the more long-term economic, business, environmental, societal and technological challenges and opportunities are just beginning to become visible.

To help all stakeholders communities, governments, businesses and individuals understand the emerging risks and follow-on effects generated by the impact of the coronavirus pandemic, the World Economic Forum, in collaboration with Marsh and McLennan and Zurich Insurance Group, has launched its COVID-19 Risks Outlook: A Preliminary Mapping and its Implications - a companion for decision-makers, building on the Forums annual Global Risks Report.

The report reveals that the economic impact of COVID-19 is dominating companies risks perceptions.

Companies are invited to join the Forums work to help manage the identified emerging risks of COVID-19 across industries to shape a better future. Read the full COVID-19 Risks Outlook: A Preliminary Mapping and its Implications report here, and our impact story with further information.

Majority of infected people never show classic symptoms

More than two thirds of people infected with coronavirus in Lombardy the epicentre of the outbreak in Italy did not display symptoms, according to new unpublished research.

Researchers studied people in Lombardy who had had close contact with an infected person. Roughly half of these 5,484 contacts became infected themselves. Of those, 31% developed respiratory symptoms or a fever and only 26% of those under the age of 60 did so.

As a persons age increased, so did their odds of experiencing symptoms and becoming ill enough to require intensive care, or to die.

Possible higher risk for blood group A

Genome-wide association studies are a relatively new way for scientists to identify genes involved in human disease. This method searches the complete set of genes known as the genome for small variations that occur more frequently in people with a particular disease than in people without the disease.

A genomewide association study involving 1,980 patients with Covid-19 at hospitals in the Italian and Spanish epicentres of the European pandemic, reveals that people with blood type A have an elevated risk compared to non-type A individuals.]

Original post:
COVID-19: Top science stories of the week, including new diabetes link and the latest Beijing - World Economic Forum

The "Diabetes Care Devices Market by Type (SMBG, CGMS, Lancets, Insulin Pumps, Insulin Pens, Insulin Syringes, Mobile Apps), Patient Care Settings (Hospitals & Specialty Clinics, Self & Home Care), and Country (Brazil, Russia, India, China) - Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

The diabetes care devices (BRIC) market size is projected to reach USD 4.3 billion by 2025 from USD 1.7 billion in 2020, at a CAGR of 16.2% during the forecast period.

The growth in this market is primarily attributed to the sharp increase in diabetes, increasing awareness of diabetes management due to the rising number of diabetes awareness campaigns and screening camps, favorable national health strategies, and government-led endorsement of medical devices.

By type, under the insulin delivery devices segment, insulin pens to hold the largest share during the forecast period

Within the type category, the diabetes care devices (BRIC) market has been segmented into blood glucose monitoring systems, insulin delivery devices, and diabetes management mobile applications. Within the insulin delivery devices segment, insulin pens held the largest share in the market. The increasing affordability of insulin pens, convenience, ease-of-use, and technological advancements in these devices that promote integrated diabetes management support the growth of this segment.

By end-user, the self/ home healthcare segment is expected to grow at a higher rate during the forecast period (2020-2025)

Based on end-user, the diabetes care devices (BRIC) market has been segmented into hospital & specialty clinics and self/home healthcare. The self/home healthcare segment is expected to grow at a higher CAGR due to the increasing awareness of self-management of diabetes, increasing portability of diabetes care devices, and technological innovations that provide real-time insights for patients and healthcare providers for decision-making regarding diabetes control and treatment planning.

India is projected to grow at the highest CAGR

China is expected to account for the largest share of the diabetes care devices (BRIC) market in 2019. The large share of this region can primarily be attributed to the sharp increase in the diabetic population in the past decade and endorsements of medical devices by the government. On the other hand, India is expected to witness the highest CAGR during the forecast period due to the increasing government investment in the medical devices industry, high prevalence of type 1 and gestational diabetes cases, and increasing diabetes awareness creation through campaigns and screening camps.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights

5 Industry Insights

6 Diabetes Care Devices Market, by Type

7 Diabetes Care Devices Market, by Patient Care Settings

7.1 Introduction

7.2 Self/Home Healthcare

7.3 Hospitals & Diabetes Specialty Clinics

8 Diabetes Care Devices Market in BRIC Countries

8.1 Introduction

8.2 China: Diabetes Care Devices Market

8.2.1 Introduction

8.2.2 Market Drivers

8.2.2.1 Sharp Increase in Diabetes in the Past Decade

8.2.2.2 Favorable National Health Strategies

8.2.2.3 Government-Led Endorsement of the Medical Device Industry

8.2.3 Market Restraints

8.2.3.1 Traditional Chinese Medicine As an Alternative

8.2.3.2 High Cost of Advanced Diabetes Management Devices

8.2.4 Market Opportunities

8.2.4.1 Significant Advancements and Leveraging of Artificial Intelligence and Big Data

8.2.5 Market Challenges

8.2.5.1 Lack of Adherence of Patients to Recommended Diabetes Treatment Guidelines

8.3 India: Diabetes Care Devices Market

8.3.1 Introduction

8.3.2 Market Drivers

8.3.2.1 High Prevalence of Diabetes

8.3.2.2 Government's Make in India Campaign to Encourage Local Manufacturing of Medical Devices

8.3.2.3 Diabetes Awareness Campaigns and Screening Camps

8.3.3 Market Restraints

8.3.3.1 Lack of Accessibility to Healthcare

8.3.3.2 Inadequate Health Insurance Coverage

8.3.4 Market Opportunities

8.3.4.1 Rising Adoption of Mhealth

8.3.5 Market Challenges

8.3.5.1 Shortage of Healthcare Professionals in Diabetes Management

8.4 Brazil: Diabetes Care Devices Market

8.4.1 Introduction

8.4.2 Market Drivers

8.4.2.1 High Prevalence of Diabetes

8.4.2.2 Favorable Government Policies

Story continues

8.4.3 Market Restraints

8.4.3.1 Lack of Awareness of Diabetes Care

8.4.3.2 High Prices of Advanced Diabetes Care Devices

8.4.4 Market Opportunities

8.4.4.1 Increasing Penetration of Smartphones and Rising Focus on Digital Health to Drive the Growth of Diabetes Management Platforms and Diabetes Management Mobile Applications

8.4.5 Market Challenges

8.4.5.1 Strict Regulatory Guidelines and Regulatory Process for Medical Devices

8.5 Russia: Diabetes Care Devices Market

8.5.1 Introduction

8.5.2 Market Drivers

8.5.2.1 Rising Elderly Population

8.5.2.2 Increasing Rate of Obesity

8.5.3 Market Restraints

8.5.3.1 Large Number of Undiagnosed Diabetics

8.5.4 Market Opportunities

8.5.4.1 Government Spending on Healthcare

8.5.4.2 Rising Investment of Pharma Market Players to Establish Local Manufacturing Plants

8.5.5 Market Challenges

8.5.5.1 Low Adoption of Glucose Monitoring Systems

9 Competitive Landscape

9.1 Overview

9.2 Product Benchmarking

9.3 Geographic Reach of the Top Market Players (2019)

9.4 R&D Expenditure: Key Players in the Diabetes Care Devices (Bric) Market

9.5 Market Share Analysis

10 Company Profiles

10.1 F. Hoffman-La Roche Ltd.

10.2 Abbott

10.3 Ascensia Diabetes Care Holdings Ag

10.4 Dexcom, Inc.

10.5 Medtronic Plc

10.6 B. Braun Melsungen Ag

10.7 Becton, Dickinson and Company

10.8 Acon Laboratories, Inc.

10.9 Arkray, Inc.

10.10 Sanofi

10.11 Novo Nordisk A/S

10.12 Terumo Corporation

10.13 Ypsomed

10.14 Sinocare, Inc.

10.15 Agamatrix Holdings Llc

10.16 Lifescan

10.17 Sd Biosensor, Inc.

10.18 Microgene Diagnostic Systems Pvt. Ltd.

10.19 Dr. Morepen

10.20 Bionime Corporation

See original here:
Diabetes Care Devices Market by Type, Patient Care Settings, and Country - BRIC Forecast to 2025 - ResearchAndMarkets.com - Yahoo Singapore News

Vancouver, British Columbia--(Newsfile Corp. - June 29, 2020) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H)("PreveCeutical"), is pleased to announce that it has successfully designed, screened and shortlisted a panel of smart-siRNA constructs with potent gene silencing activity (in vitro) in its Dual Gene Therapy Research Program.

This further update to the Company's Dual Gene Therapy Program, (see earlier release on January 14, 2020), is an important and fundamental aspect which involves deriving Smart-siRNA constructs, effective in downregulating the Company's target gene of interest, in type 2 diabetes and obesity.

The Company is very pleased to confirm that it has now shortlisted a panel of Smart-siRNA constructs considered novel in their sequence and chemistry. The panel of Smart-siRNA constructs incorporate a proprietary chemistry, adding to their novelty. In the next phase, this construct's biostability will be essential for assessment in preclinical (mice) models of type 2 diabetes and obesity.

The Company can confirm that a number of siRNA drug delivery systems were evaluated in a 3-dimensional liver tissue assay. The 3D liver tissue assay mimics the 3D architecture and microenvironment of the liver, so it is closer to the real-life biological environment than the 2D testing. Ongoing work aims to determine the optimal drug delivery technology with the Smart-siRNA with the desirable properties, including biostability, the release of the siRNA cargo when exposed to physiological intracellular conditions and no evidence of cellular toxicity.

The Company may consider filing a patent application to protect the siRNA sequences, the Smart-siRNA constructs and related intellectual property arising from this Program.

The Company's President and Chief Scientific Officer, Dr. Makarand Jawadekar, commented, "We are very happy with the progress of our Programs to date with UniQuest. The outcomes from this Program will definitely add IP to PreveCeutical's growing IP portfolio, enhancing our "out-licensing" technologies strategy with bigger Pharma companies and helping their commercialization of new products".

About PreveCeutical

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.

PreveCeutical aims to be a leader in preventive health sciences. The Company's current research and development programs include dual gene curative and preventive therapies for diabetes and obesity; the Cannabidiols Sol-gel Program aiming to provide relief across a range of indications from pain, inflammation, seizures, and neurological disorders.; Nature Identical peptides for the treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

For more information about PreveCeutical, please visit our website http://www.PreveCeutical.com or follow us on Twitter and Facebook.

On behalf of the Board of Directors of PreveCeutical

Stephen Van Deventer, Chairman and Chief Executive Officer

For further information, please contact:

Stephen Van Deventer: +1 604 306 9669

Or Investor Relations ir@preveceutical.com

Forward-Looking Statements:

This news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, the completion of one aspect of the current phase of the Dual Gene Therapy Program, the efficacy of the Company's products, matters related to the Company's current and planned research and development programs, including the Dual Gene Therapy Program, the efficacy of the panel of siRNA constructs and the efficacy, biostability and potency of the Smart-siRNAs, the Company's anticipated future business plans and its prospect of success in executing thereon. Often, but not always, forward-looking statements can be identified by words such as "will", "plans", "expects", "may", "intends", "anticipates", "believes", "proposes" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Forward-looking statements are based on certain assumptions regarding the Company, including expected growth, results of operations and research and development activities (including in respect of the successful completion of the Dual Gene Therapy Program and one aspect of its current phase), performance, industry trends, growth opportunities, and that the Company will be able to obtain the financing required to carry out its planned future business activities, retain and attract qualified research personnel and obtain and/or maintain the necessary intellectual property rights it needs to carry out its future business activities.

Story continues

Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to the completion of the Dual Gene Therapy Program and one aspect of its current phase, actual results of research and development programs, the inability of the Company, to, among other things, protect its intellectual property, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities, commercialize any therapeutic and diagnostic technologies, execute its proposed business plans, pursue business partnerships, complete its research and development programs as planned, including the Dual Gene Therapy Program, and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology, pharmaceutical or cannabis industry may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, intentions and assumptions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, intentions or assumptions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company's filings are available at http://www.sedar.com.

Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/58765

See the rest here:
PreveCeutical Announces Promising 3D Liver Tissue Testing of Potential Therapy for Diabetes and Obesity - Yahoo Finance

To discourage people with hypertension and diabetes from visiting government hospitals amid rising cases of COVID-19, the Health department is delivering medicines at their doorsteps.

Doctors and officials have stressed that COVID-19 patients with co-morbidities are at higher risk of developing complications. The elderly and those with co-morbidities have been advised to stay indoors. Besides, during the lockdown from March 23 to May 31, people found it hard to get medicines as transportation also come to a halt.

Officials from the Commissioner of Health and Family Welfare wing said they initiated the process of delivering medicines at the doorstep of patients from March year when coronavirus cases had started to emerge in Telangana.

Under Non Communicable Disease (NCD) screening programme last year, 1.1 crore adults were screened for the two diseases. Of them, around 10.98 lakh with hypertension and 5.50 lakh with diabetes were diagnosed, and receiving treatment in both public and private healthcare facilities.

After initial screening of people above the age of 30 years by Auxiliary Nursing Midwives (ANMs), if abnormal blood pressure or blood sugar levels are recorded, the person is referred to Primary Health Centre (PHC) medical officer who conducts another round of diagnosis to confirm the readings. If abnormalities are recorded, the patient is put on treatment.

Till mid-2019, medicines for NCD were distributed to patients on a monthly basis at Primary Health Centres (PHC).Thereafter, the distribution process was decentralised in Telangana, under the India Hypertension Control Initiative.

Refilling drugs was shifted to sub-centres through ANMs so that patients, especially the elderly who constitute a majority of the patients, dont have to travel long distances to reach a PHC for the medicines or check-ups.

If the readings were not abnormal during subsequent check-ups, medicines were issued based on prescription issued by PHC Medical officer. Officials said they issued treatment booklets with details of blood pressure or blood sugar readings, medicines issued, etc. However, if ANMs recorded abnormal readings during the subsequent check-ups, the patients were again referred to the PHC medical officer who further examined and escalated the drugs, if necessary.

However, after imposition of lockdown, patients were unable to travel to get medicines. So, a decision was taken to deliver drugs on a monthly basis by the ANMs to their doorstep. The number of diabetes and hypertension patients receiving treatment in the government sector was 6.5 lakh in March which increased to 8.27 lakh in April and was estimated to be around 8.7 lakh for May 2020, Health officials said.

As ANMs go door to door to deliver medicines, they are provided masks, face shields and gloves.

You have reached your limit for free articles this month.

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Enjoy reading as many articles as you wish without any limitations.

A select list of articles that match your interests and tastes.

Move smoothly between articles as our pages load instantly.

A one-stop-shop for seeing the latest updates, and managing your preferences.

We brief you on the latest and most important developments, three times a day.

Not convinced? Know why you should pay for news.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

Continue reading here:
Medicines at the doorstep for those with hypertension and diabetes - The Hindu

The global wound closure products market is a highly competitive market with a high number of global and local players operating in it around the world, states a new market research study by Transparency Market Research. The key players in the market are focusing on the expansion of the product portfolio and the innovations, which is expected to support the growth of the overall market in the next few years. In addition to this, the rising research and development activities and technological developments are projected to enhance the growth of the market in the next few years.

Furthermore, the rising collaborations and mergers and acquisitions are projected to generate potential growth opportunities for the market players throughout the forecast period. Some of the key players operating in the wound closure products market across the globe are Covidien plc, Baxter International, Inc., Johnson & Johnson (Ethicon), B. Braun, and Cryolife.

According to the market research study by Transparency Market Research, the global market for wound closure products is expected to reach a value of US$15.2 bn by the end of year 2023. The market is estimated to register a promising growth rate throughout the forecast period.

Request Brochure of Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=5429

High Contribution from US to Drive North America Wound Closure Products Market

Among the key regional segments, North America is expected to hold a large share of the market and is likely to remain in the leading position throughout the forecast period. The launch of new medical devices and the rising contribution from the U.S. are some of the key factors that are estimated to enhance the growth of this region in the next few years. In addition to this, the well-established healthcare sector and the presence of several leading players are some of the other key factors that are estimated to support the growth of the North America market in the next few years.

Furthermore, Europe is likely to remain at the second position with a significant share of the global market. However, Asia Pacific is estimated to offer lucrative opportunities for the players, thanks to which, this region is likely to register a strong growth rate throughout the forecast period.

Request for Analysis of COVID19 Impact on Wound Closure Products Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=5429

The global market for wound closure products on the basis of product type into surgical staples, adhesive and tissue sealants, sutures, and hemostats. Among these, the surgical staples and sutures are considered the key segments and are projected to account for a large share of the overall market in the next few years. On the other hand, with the help of technological advancements, the sealants segment is predicted to witness a healthy growth rate in the next few years. The advent of new products, thanks to the rising research and development activities is predicted to enhance the growth of this segment throughout the forecast period.

Advent of New Products to Enhance Growth of Global Wound Closure Products Market

The rising application in external as well as internal wounds and the increasing number of surgical procedures are considered as the major factors that are projected to enhance the growth of the global wound closure products in the next few years. In addition to this, the rising demand for cosmetic and plastic surgeries is another key factor that is likely to encourage the growth of the overall market throughout the forecast period.

Buy Wound Closure Products Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=5429&ltype=S

The increasing focus of key players on the research and development activities is expected to accelerate the market growth in the near future. Furthermore, the introduction of new products and the rapidly rising geriatric populations are predicted to generate potential growth opportunities for the market players in the next few years.

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 Sate Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

See more here:
Wound Closure Products Market: Increased Prevalence of Diabetes and Disabilities to Bolster Demand - Cole of Duty

Wearing comfortable and well-fitted shoes is necessary and can make your feet healthy and manage the symptoms of diabetes. Here are a few things you must look for in your shoes:

Your shoes should be 1/4 to 1/2 inch deeper than normal shoes so that you do not feel uncomfortable when dealing with calluses or hammertoes.

Instead of pointed toes, buy the one with a spacious toe box. This is will give enough room to your toes to move and reduce the chance of corns, calluses, and blisters.

Avoid high-heel and high-heeled shoes as they put excessive pressure on your foot.

Do not buy any fancy, strappy and open toe shoes. The straps put pressure on certain points of your feet, which can easily cause blisters. Even slippers are not the best option. Wear laced shoes as they provides better support and fit your feet perfectly.

Whenever planning to buy new shoes, do it at the end of the day. Our feet are swollen at the end and if your shoes fit in at that time, you would not have any problem later.

Read more:
Diabetes and foot problems: How to choose the right kind of footwear when suffering from diabetes - Times of India

The recent resurgence in diabetes-related lower-extremity amputations in the United States is not limited to younger adults, according to the author of a recent study that documents similar increases among an older population of Medicare beneficiaries.

While the rate of amputations fell among these older adults from 2000 to 2009, it increased significantly from 2009 to 2017, albeit at a "less severe rate" than recently reported in younger populations, said study investigatorJessica Harding, PhD.

The rate of nontraumatic lower extremity amputation (NLEA) was ticking upward by more than 1% per year over the 2009-2017 period, according to Dr. Harding, assistant professor in the department of surgery at Emory University, Atlanta.

This latest report follows one from last year, published in Diabetes Care, that documented an annual percentage increase approaching 6% between 2009 and 2015, driven by larger increases among adults 18-64 years of age, as well as an increase among men.

It's not clear why rates of NLEA would be on the rise among younger and older adults in the United States, Dr. Harding said, though factors she said could be implicated include changes in amputation practice, increased comorbidities, higher insulin costs, or shortcomings in early prevention programs.

"We need large-scale studies with granular data to tease out key risk factors that could help identify the drivers of these increases in amputations," Dr. Harding said in a presentation at the virtual annual scientific sessions of the American Diabetes Association.

"In the interim, increased attention to preventive foot care across the age spectrum could benefit adults with diabetes," she added.

The latest findings from Dr. Harding and coauthors emphasize the importance of a "team approach" to early prevention in older adults with diabetes, said Derek LeRoith, MD, PhD, director of research in the division of endocrinology, diabetes, and bone diseases with Icahn School of Medicine at Mount Sinai, New York.

"If you take a 75-year-old or even an 80-year-old, their life expectancy can still be a good 10 years or more," Dr. LeRoith said in an interview. "We shouldn't give up on them we should be treating them to prevent complications."

Lower-extremity amputation is a "particularly devastating" complication that can compromise mobility, ability to exercise, and motivation, according to Dr. LeRoith, lead author of a recent Endocrine Societyclinical practice guidelinethat urges referral of older adults with diabetes to a podiatrist, orthopedist, or vascular specialist for preventive care.

"Quite often, treating their glucose or high blood pressure will be much more difficult because of these changes," he said.

Rates of NLEA declined for years, only to rebound by 50%, according to authors of a recent analysis of Nationwide Inpatient Sample (NIS) data reported last year. In their report, the age-standardized diabetes-related NLEA rate per 1,000 adults with diabetes went from 5.30 in 2000, down to 3.07 in 2009/2010, and back up to 4.62 by 2015 (Diabetes Care. 2019 Jan;42:50-4).

The resurgence was fueled mainly by an increased rate of amputations in younger and middle-aged adults and men, and through increases in minor amputations, notably the toe, according to the investigators. "These changes in trend are concerning because of the disabling and costly consequences of NLEAs as well as what they may mean for the direction of efforts to reduce diabetes-related complications," authors of that report said at the time.

In the current study, Dr. Harding and colleagues included Medicare Parts A and B claims data for beneficiaries enrolled from 2000 to 2017. There were 4.6 million Medicare fee-for-service beneficiaries with diabetes in 2000, increasing to 6.9 million in 2017, she reported at the virtual ADA meeting.

Rates of NLEA followed a trajectory similar to what was seen in the earlier NIS report, falling from 8.5 per 1,000 persons in 2000 to 4.4 in 2009, for an annual percentage change of 7.9 (P< .001), Dr. Harding said. Then rates ticked upward again, to 4.8 in 2017, for an annual percentage change of 1.2 over that later period (P< .001).

While the trend was similar for most subgroups analyzed, the absolute rates were highest among men and black individuals in this older patient population, reported Dr. Harding and coauthors.

Dr. Harding said she and coauthors had no disclosures related to the research, which was performed as a collaboration between Emory University and the Centers for Disease Control and Prevention Division of Diabetes Translation.

SOURCE:Harding J. ADA 2020,Abstract 106-OR.

This article originally appeared onMDedge.com.

See the rest here:
Diabetes-Related Amputations on the Rise in Older Adults - Medscape